Patheon has completed an expansion project at its Greenville, NC manufacturing site following a $26 million investment to update one of its sterile Pharmaceutical Development Services (PDS) suites and build a new integrated sterile PDS suite. The PDS Suites provide 7,000-sq.-ft. in GMP sterile manufacturing space.

The new PDS suite will manufacture sterile liquid and lyophilized drug products. It features freeze dryers and a fully integrated filling line fitted with a Restricted Access Barrier System (RABS) for sterile drug products. The company has also invested in disposable manufacturing, reducing set up time/product losses and enhancing sterility assurance. This suite is fully integrated and designed for products in clinical development with the ability to scale up to much larger batch sizes via Patheon’s network of commercial scale capabilities either co-existing within the Greenville facility, or in Europe.

“As the industry continues to innovate, customers will require even more advanced solutions, integrating development and commercial service, to meet their business needs,” said Franco Negron, president of Patheon’s drug product and pharmaceutical development services for North America. “The increasing focus on pharma to reduce costs will lead forward-thinking companies to capitalize on their core competencies – focusing on what they do best, while strategically partnering with companies such as Patheon to deliver the expertise, customized solutions and technical capabilities to support the production of their small and large molecule products.”

Patheon’s Greenville, NC manufacturing site provides both solid dose form manufacturing/packaging and sterile dose manufacturing, filling and lyophilization of both biopharmaceuticals and small molecules.